Ravicti (Glycerol Phenylbutyrate) Patent Expiration, LOE Window & CMS Spending

Ravicti (Glycerol Phenylbutyrate) by Amgen: FDA Orange Book LOE 2030-09-22, 0 AB generics, $344.1M 2024 CMS Part D & Medicaid spend, and $1,597 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN203284 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-09-22
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$344.1M
2024 Medicare Part D Spend$79.5M
2024 Medicaid Spend$264.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,597 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.